title: Personalized Comments on Challenges and Opportunities in Kidney Disease Therapeutics: The Glom-NExT Symposium.
abstract: In the face of ever-increasing incidence and prevalence of kidney disease worldwide, the unmet need for new treatments is unprecedented. Precision medicine is defined as the use of modern technologies to identify mechanisms of diseases in individual patients, and thus deploy treatment using tailored, targeted approaches, in the hopes of avoiding unnecessary toxicities and complications. Is there a place for kidney disease therapeutics in this space? If so, what is required to make significant progress toward precision nephrology? To answer these critical questions, we present a series of personalized comments corresponding to the responses offered to these very questions during the Inaugural Glom-NExT Symposium held at Harvard Medical School on October 23, 2014, a national meeting focused exclusively on kidney disease therapeutics.
authors.affiliation: Department of Medicine and Glom-NExT Center for Glomerular Kidney Disease and Novel Experimental Therapeutics, Renal Division, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; Broad Institute of Massachusetts Institute of Technology, and Harvard, Cambridge, MA. Electronic address: agreka@bwh.harvard.edu.
authors.forename: Anna
authors.initials: A
authors.lastname: Greka
authors.affiliation: Department of Pediatrics, University of Michigan School of Medicine, Ann Arbor, MI.
authors.forename: Deb
authors.initials: D
authors.lastname: Gibson
authors.affiliation: Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.
authors.forename: Peter
authors.initials: P
authors.lastname: Mundel
authors.affiliation: Dana Farber Cancer Institute and Brigham and Women's Hospital, Harvard Medical School, Boston, MA.
authors.forename: George
authors.initials: G
authors.lastname: Demetri
authors.affiliation: Department of Medicine, Division of Nephrology, Children's Hospital and Harvard Medical School, Boston, MA.
authors.forename: Friedhelm
authors.initials: F
authors.lastname: Hildebrandt
authors.affiliation: Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.
authors.forename: Martin
authors.initials: M
authors.lastname: Pollak
authors.affiliation: Broad Institute of Massachusetts Institute of Technology, and Harvard, Cambridge, MA; Center for Human Genetic Research and Diabetes Research Center, Diabetes Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
authors.forename: Jose
authors.initials: J
authors.lastname: Florez
mesh_terms: D006801:Humans; D007674:Kidney Diseases / Q000628:therapy*; D009398:Nephrology; D057285:Precision Medicine
keywords: ADCK4; APOL1; ARHGDIA; Adaptive trials; B7-1; CD80; COQ6; FSGS; INF2; Rac1; TRPC5; TRPC6; actinin-4; autosomal dominant; clinical trials; consortium; cytoskeleton; integrin; kidney disease; nephrotic syndrome; patient-reported outcomes; podocyte; precision medicine; proteinuria; rare disease; recessive mutations; synaptopodin; targeted therapy